Target intelligence / Profile preview

SARS-CoV-2 spike (S), nucleocapsid (N), and membrane (M) protein epitopes (SARS-CoV-2 S/N/M epitopes)

Target
SARS-CoV-2 S/N/M epitopes
Molecular classification
Viral protein, Antigen, Surface glycoprotein (Spike), RNA-binding protein (Nucleocapsid)
01

Overview

SARS-CoV-2 spike, nucleocapsid, and membrane protein epitopes are the key molecular fragments of the SARS-CoV-2 virus recognized by the human immune system. The Spike (S) protein is a large transmembrane glycoprotein that mediates viral attachment and membrane fusion via the ACE2 receptor, making it the primary target for neutralizing antibodies and most first-generation vaccines (UniProt P0DTC2). The Nucleocapsid (N) protein is an internal protein that binds to the viral RNA genome, playing a vital role in viral replication and assembly, and is highly immunogenic for T-cell responses (UniProt P0DTC9). The Membrane (M) protein is the most abundant structural protein, essential for organizing the viral assembly process and maintaining the envelope structure (UniProt P0DTC5). Together, these epitopes are utilized in the development of diagnostic assays, multi-antigen vaccines, and adoptive T-cell therapies to provide comprehensive immunity against COVID-19. Therapeutic strategies targeting these proteins aim to block viral entry, inhibit replication, or clear infected cells through cytotoxic T-lymphocyte activity.

Other names
SARS-CoV-2 structural protein epitopesSARS-CoV-2 S, N, and M antigensSevere acute respiratory syndrome coronavirus 2 structural proteinsS/N/M protein fragments
02

Mechanism of action

Neutralization of viral entry by blocking the receptor-binding domain (RBD) of the Spike protein, and induction of T-cell mediated cytotoxicity against cells presenting Spike, Nucleocapsid, or Membrane epitopes.

03

Biological functions

Viral entryViral assemblyRNA packagingImmune responseViral replication
04

Disease associations

InfectionCOVID-19
05

Safety considerations

Viral escape due to mutations in epitope regions (antigenic drift)Potential for antibody-dependent enhancement (ADE)Risk of cytokine release syndrome in advanced T-cell therapies
06

Interacting drugs

BNT162b2 (Comirnaty)

8 more in the full profile.

07

Biomarkers

Anti-Spike IgG/IgM titersAnti-Nucleocapsid antibodiesInterferon-gamma release assays (IGRA)Viral load (RT-PCR)

Beyond the preview

Go deeper on SARS-CoV-2 spike (S), nucleocapsid (N), and membrane (M) protein epitopes (SARS-CoV-2 S/N/M epitopes).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SARS-CoV-2 spike (S), nucleocapsid (N), and membrane (M) protein epitopes (SARS-CoV-2 S/N/M epitopes).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call